Market Research Logo

Phototherapy Treatment Market for Acne and Psoriasis North America and Europe Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Phototherapy Treatment Market for Acne and Psoriasis North America and Europe Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Family physicians are playing a crucial role in diagnosing psoriasis in Canada

In Canada, the majority of the psoriasis patients are mainly diagnosed by family physicians rather than by dermatologists. The reason behind this is the lack of dermatologists and related services in Canada. For instance, according to a report published by the Economist Intelligence Unit, Canada had less than 2 dermatologists per 100,000 individuals in 2015, which is very less when compared with European countries. It has also been observed that family physicians typically prefer topical therapies than biologics/phototherapy to treat psoriasis conditions, while dermatologists prefer phototherapy more than the other available therapies/medications. This recent trend is boosting the phototherapy segment. While in the U.S. the growing population of adult women suffering from acne and psoriasis is an important factor driving revenue growth of the phototherapy segment. The population of adult women is rising with higher rates in North America than in European countries such as Germany, Italy, France and Spain. The growth in women adult acne conditions in North America is mainly due to increase in male hormonal (androgens) levels in females.

Complementary therapies to treat psoriasis conditions and combination therapies are recent trends in Western Europe, which are creating a positive impact on the phototherapy segment in the regional market

Complementary therapies such as balneotherapy along with UV radiation is quite popular in Western European countries. Balneotherapy is the oldest treatment method available to treat the psoriasis condition. In this treatment, the patient undergoes a bath in high mineralized brine, which causes a mechanical removal of skin scales and increases the sensitivity of skin to UV radiation. Combination therapies are set to witness high potential in austerity driven markets in Europe as noted by many clinic managers. Faltering out-of-pocket expenses for a service that is considered as a desire or luxury coupled with a tricky pricing of combination treatments involving a device and a drug are factors successfully helping in generating revenue in the market. This trend is very prominent in countries such as the U.K. and Spain. Approved by the FDA to treat acne and psoriasis, blue light therapy dominates the North America and Europe phototherapy treatment market

By phototherapy type, blue light therapy dominated the North America and Europe phototherapy treatment market for psoriasis and acne, and is expected to be the most lucrative segment over the forecast period, with a market attractiveness index of 3.3. By the end of 2027, the blue light phototherapy segment is projected to reach more than US$ 1,000 Mn, expanding at a CAGR of 6.7% over the forecast period. Revenue from the Narrowband UVB phototherapy segment in the North America and Europe phototherapy treatment market for psoriasis and acne is expected to grow 1.9x by 2027 end as compared to that in 2017. The Red Light Phototherapy and Intense Pulsed Light (IPL) Phototherapy segments represent the lowest market attractiveness index of 0.3 each.

Availability of various treatments for acne and psoriasis and declining reimbursement rates are expected to hamper the growth of the phototherapy segment

Various treatments are currently available in the market to treat acne and psoriasis conditions. For instance, to treat acne conditions various drugs are available in the market such as topical/oral antibiotics and retinoid and chemical peels, among others. Due to a lot of available treatment options, physicians prescribe different treatments according to the patient’s skin nature and availability of drugs. Owing to the many treatment options, very few physicians prescribe phototherapy to patients. Furthermore, availability of non-office based treatments to treat acne and psoriasis conditions has a negative impact on the growth of the phototherapy segment. Furthermore, the decline of reimbursement pay and lack of adequate phototherapy units in the market are projected to hamper revenue growth of the phototherapy segment over the forecast period.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Phototherapy Treatment Market Overview
3. Medical Bionic Implants & Exoskeletons Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Pricing Assumptions
4. North America Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012-2016
4.5.1. Psoriasis
4.5.1.1. Guttate Psoriasis
4.5.1.2. Inverse Psoriasis
4.5.1.3. Pustular Psoriasis
4.5.1.4. Erythrodermic Psoriasis
4.5.1.5. Plaque Psoriasis
4.5.2. Acne
4.5.2.1. Acne Vulgaris
4.5.2.2. Acne Conglobata
4.5.2.3. Acne Fulminans
4.5.2.4. Gram-Negative Folliculitis
4.5.2.5. Acne Rosacea
4.5.2.6. Pyoderma Faciale
4.6. Market Size (US$ Mn) Forecast By Disease Type, 2017-2027
4.6.1. Psoriasis
4.6.1.1. Guttate Psoriasis
4.6.1.2. Inverse Psoriasis
4.6.1.3. Pustular Psoriasis
4.6.1.4. Erythrodermic Psoriasis
4.6.1.5. Plaque Psoriasis
4.6.2. Acne
4.6.2.1. Acne Vulgaris
4.6.2.2. Acne Conglobata
4.6.2.3. Acne Fulminans
4.6.2.4. Gram-Negative Folliculitis
4.6.2.5. Acne Rosacea
4.6.2.6. Pyoderma Faciale
4.7. Historical Market Size (US$ Mn) Analysis By Phototherapy, 2012-2016
4.7.1. Blue Light Phototherapy
4.7.2. Red Light Phototherapy
4.7.3. Intense Pulsed Light (IPL) Phototherapy
4.7.4. Combination Treatment
4.7.5. Narrowband UVB Phototherapy
4.7.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
4.7.7. Others
4.8. Market Size (US$ Mn) Forecast By Phototherapy, 2017-2027
4.8.1. Blue Light Phototherapy
4.8.2. Red Light Phototherapy
4.8.3. Intense Pulsed Light (IPL) Phototherapy
4.8.4. Combination Treatment
4.8.5. Narrowband UVB Phototherapy
4.8.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
4.8.7. Others
4.9. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
4.9.1. Hospitals
4.9.2. Dermatology Clinics/Skin Care Centers
4.9.3. Wellness Centers
4.9.4. Home Care Settings
4.10.Market Size (US$ Mn) Forecast By End User, 2017-2027
4.10.1. Hospitals
4.10.2. Dermatology Clinics/Skin Care Centers
4.10.3. Wellness Centers
4.10.4. Home Care Settings
4.11.Market Attractiveness Analysis
4.11.1. By Country
4.11.2. By Disease Type
4.11.3. By Phototherapy
4.11.4. By End User
5. Western Europe Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
5.3.1. Germany
5.3.2. United Kingdom
5.3.3. France
5.3.4. Italy
5.3.5. Spain
5.3.6. Nordics
5.3.7. BENELUX
5.3.8. Rest of Western Europe
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1. Germany
5.4.2. United Kingdom
5.4.3. France
5.4.4. Italy
5.4.5. Spain
5.4.6. Nordics
5.4.7. BENELUX
5.4.8. Rest of Western Europe
5.5. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012-2016
5.5.1. Psoriasis
5.5.1.1. Guttate Psoriasis
5.5.1.2. Inverse Psoriasis
5.5.1.3. Pustular Psoriasis
5.5.1.4. Erythrodermic Psoriasis
5.5.1.5. Plaque Psoriasis
5.5.2. Acne
5.5.2.1. Acne Vulgaris
5.5.2.2. Acne Conglobata
5.5.2.3. Acne Fulminans
5.5.2.4. Gram-Negative Folliculitis
5.5.2.5. Acne Rosacea
5.5.2.6. Pyoderma Faciale
5.6. Market Size (US$ Mn) Forecast By Disease Type, 2017-2027
5.6.1. Psoriasis
5.6.1.1. Guttate Psoriasis
5.6.1.2. Inverse Psoriasis
5.6.1.3. Pustular Psoriasis
5.6.1.4. Erythrodermic Psoriasis
5.6.1.5. Plaque Psoriasis
5.6.2. Acne
5.6.2.1. Acne Vulgaris
5.6.2.2. Acne Conglobata
5.6.2.3. Acne Fulminans
5.6.2.4. Gram-Negative Folliculitis
5.6.2.5. Acne Rosacea
5.6.2.6. Pyoderma Faciale
5.7. Historical Market Size (US$ Mn) Analysis By Phototherapy, 2012-2016
5.7.1. Blue Light Phototherapy
5.7.2. Red Light Phototherapy
5.7.3. Intense Pulsed Light (IPL) Phototherapy
5.7.4. Combination Treatment
5.7.5. Narrowband UVB Phototherapy
5.7.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
5.7.7. Others
5.8. Market Size (US$ Mn) Forecast By Phototherapy, 2017-2027
5.8.1. Blue Light Phototherapy
5.8.2. Red Light Phototherapy
5.8.3. Intense Pulsed Light (IPL) Phototherapy
5.8.4. Combination Treatment
5.8.5. Narrowband UVB Phototherapy
5.8.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
5.8.7. Others
5.9. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
5.9.1. Hospitals
5.9.2. Dermatology Clinics/Skin Care Centers
5.9.3. Wellness Centers
5.9.4. Home Care Settings
5.10.Market Size (US$ Mn) Forecast By End User, 2017-2027
5.10.1. Hospitals
5.10.2. Dermatology Clinics/Skin Care Centers
5.10.3. Wellness Centers
5.10.4. Home Care Settings
5.11.Market Attractiveness Analysis
5.11.1. By Country
5.11.2. By Disease Type
5.11.3. By Phototherapy
5.11.4. By End User
6. Eastern Europe Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
6.3.1. Russia
6.3.2. Poland
6.3.3. Rest of Eastern Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1. Russia
6.4.2. Poland
6.4.3. Rest of Eastern Europe
6.5. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012-2016
6.5.1. Psoriasis
6.5.1.1. Guttate Psoriasis
6.5.1.2. Inverse Psoriasis
6.5.1.3. Pustular Psoriasis
6.5.1.4. Erythrodermic Psoriasis
6.5.1.5. Plaque Psoriasis
6.5.2. Acne
6.5.2.1. Acne Vulgaris
6.5.2.2. Acne Conglobata
6.5.2.3. Acne Fulminans
6.5.2.4. Gram-Negative Folliculitis
6.5.2.5. Acne Rosacea
6.5.2.6. Pyoderma Faciale
6.6. Market Size (US$ Mn) Forecast By Disease Type, 2017-2027
6.6.1. Psoriasis
6.6.1.1. Guttate Psoriasis
6.6.1.2. Inverse Psoriasis
6.6.1.3. Pustular Psoriasis
6.6.1.4. Erythrodermic Psoriasis
6.6.1.5. Plaque Psoriasis
6.6.2. Acne
6.6.2.1. Acne Vulgaris
6.6.2.2. Acne Conglobata
6.6.2.3. Acne Fulminans
6.6.2.4. Gram-Negative Folliculitis
6.6.2.5. Acne Rosacea
6.6.2.6. Pyoderma Faciale
6.7. Historical Market Size (US$ Mn) Analysis By Phototherapy, 2012-2016
6.7.1. Blue Light Phototherapy
6.7.2. Red Light Phototherapy
6.7.3. Intense Pulsed Light (IPL) Phototherapy
6.7.4. Combination Treatment
6.7.5. Narrowband UVB Phototherapy
6.7.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
6.7.7. Others
6.8. Market Size (US$ Mn) Forecast By Phototherapy, 2017-2027
6.8.1. Blue Light Phototherapy
6.8.2. Red Light Phototherapy
6.8.3. Intense Pulsed Light (IPL) Phototherapy
6.8.4. Combination Treatment
6.8.5. Narrowband UVB Phototherapy
6.8.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
6.8.7. Others
6.9. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
6.9.1. Hospitals
6.9.2. Dermatology Clinics/Skin Care Centers
6.9.3. Wellness Centers
6.9.4. Home Care Settings
6.10.Market Size (US$ Mn) Forecast By End User, 2017-2027
6.10.1. Hospitals
6.10.2. Dermatology Clinics/Skin Care Centers
6.10.3. Wellness Centers
6.10.4. Home Care Settings
6.11.Market Attractiveness Analysis
6.11.1. By Country
6.11.2. By Disease Type
6.11.3. By Phototherapy
6.11.4. By End User
7. Forecast Factors: Relevance and Impact
8. Forecast Assumptions
9. Competition Landscape
9.1. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
9.1.1. Lifespan
9.1.2. UC Irvine Health
9.1.3. Buffalo Medical Group
9.1.4. Blackrock Clinic Limited
9.1.5. The Private Phototherapy Clinic Ltd
9.1.6. National Skin Centre
9.1.7. Massachusetts General Hospital
10. North America and Europe Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027, By Region
10.1.Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
10.1.1. North America
10.1.2. Western Europe
10.1.3. Eastern Europe
10.2.Market Size (US$ Mn) Forecast By Region, 2017-2027
10.2.1. North America
10.2.2. Western Europe
10.2.3. Eastern Europe
10.3.Market Attractiveness Analysis By Region
11. North America and Europe Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027, By Disease
11.1.Introduction/Key Finding
11.2.Historical Market Size (US$ Mn) Analysis By Disease, 2012-2016
11.2.1. Psoriasis
11.2.1.1. Guttate Psoriasis
11.2.1.2. Inverse Psoriasis
11.2.1.3. Pustular Psoriasis
11.2.1.4. Erythrodermic Psoriasis
11.2.1.5. Plaque Psoriasis
11.2.2. Acne
11.2.2.1. Acne Vulgaris
11.2.2.2. Acne Conglobata
11.2.2.3. Acne Fulminans
11.2.2.4. Gram-Negative Folliculitis
11.2.2.5. Acne Rosacea
11.2.2.6. Pyoderma Faciale
11.3.Market Size (US$ Mn) Forecast By Disease, 2017-2027
11.3.1. Psoriasis
11.3.1.1. Guttate Psoriasis
11.3.1.2. Inverse Psoriasis
11.3.1.3. Pustular Psoriasis
11.3.1.4. Erythrodermic Psoriasis
11.3.1.5. Plaque Psoriasis
11.3.2. Acne
11.3.2.1. Acne Vulgaris
11.3.2.2. Acne Conglobata
11.3.2.3. Acne Fulminans
11.3.2.4. Gram-Negative Folliculitis
11.3.2.5. Acne Rosacea
11.3.2.6. Pyoderma Faciale
11.4.Market Attractiveness Analysis By Disease
12. North America and Europe Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027, By Phototherapy
12.1.Introduction/Key Finding
12.2.Historical Market Size (US$ Mn) Analysis By Mode, 2012-2016
12.2.1. Blue Light Phototherapy
12.2.2. Red Light Phototherapy
12.2.3. Intense Pulsed Light (IPL) Phototherapy
12.2.4. Combination Treatment
12.2.5. Narrowband UVB Phototherapy
12.2.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
12.2.7. Others
12.3.Market Size (US$ Mn) Forecast By Mode, 2017-2027
12.3.1. Blue Light Phototherapy
12.3.2. Red Light Phototherapy
12.3.3. Intense Pulsed Light (IPL) Phototherapy
12.3.4. Combination Treatment
12.3.5. Narrowband UVB Phototherapy
12.3.6. Psoralens+Ultraviolet light A (PUVA) Phototherapy
12.3.7. Others
12.4.Market Attractiveness Analysis By Phototherapy
13. North America and Europe Phototherapy Treatment Market for Psoriasis & Acne Analysis 2012–2016 and Forecast 2017–2027, By End User
13.1.Introduction/Key Finding
13.2.Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
13.2.1. Hospitals
13.2.2. Dermatology Clinics/Skin Care Centers
13.2.3. Wellness Centers
13.2.4. Home Care Settings
13.3.Market Size (US$ Mn) Forecast By End User, 2017-2027
13.3.1. Hospitals
13.3.2. Dermatology Clinics/Skin Care Centers
13.3.3. Wellness Centers
13.3.4. Home Care Settings
13.4.Market Attractiveness Analysis By End User

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report